Reporting of adverse drug reactions by poison control centres in the US
- PMID: 10915034
- DOI: 10.2165/00002018-200023010-00006
Reporting of adverse drug reactions by poison control centres in the US
Abstract
Background: Although US poison control centres manage approximately 30,000 adverse drug reactions each year, the extent of voluntary reporting of these events to the US Food and Drug Administration (FDA) MedWatch spontaneous surveillance programme is unknown.
Methods: A survey was mailed to directors of all 72 US poison control centres during April 1999 to determine their practices and opinions on reporting adverse drug reactions. The survey requested information on the poison control centre staff's practices in reporting adverse drug reactions to the FDA MedWatch programme during 1998.
Results: A total of 56 fully completed surveys were returned. Of the respondents, 30 had not directly submitted adverse drug reaction reports to the FDA, 22 had submitted 10 or less, and 4 had submitted a total of 47 during 1998. Reasons given for not routinely reporting adverse drug reactions included adverse drug reactions reporting is not part of the regular routine (20%), lack of time to complete forms (15%), inability to determine causality (13%), most reactions are already reported and not unique (10%), reporting to the FDA is too much work (9%), and responsibility rests with the attending physician (7%). Direct reporting to MedWatch of any cases of adverse drug reactions was more likely when the poison control centre was certified by the American Association of Poison Control Centers (p < 0.05; odds ratio = 5.1; 95% confidence interval 1.1 to 23.5); however, this practice was not associated with documenting deaths associated with adverse drug reactions, having more than 75% of the staff of the Poison Information Specialists composed of pharmacists or nurses, or managing greater than 20,000 or 34,000 human exposure cases during 1998. Approximately half of the poison control centres directly or indirectly reported some adverse drug reactions to the FDA by virtue of contacting the manufacturer or cooperating with postmarketing surveillance.
Conclusion: Poison control centres represent an underutilised source of reporting to MedWatch, but several internal and external obstacles limit the direct reporting of adverse drug reactions routinely.
Similar articles
-
Role of US poison centers in adverse drug reactions monitoring.Vet Hum Toxicol. 1999 Dec;41(6):400-2. Vet Hum Toxicol. 1999. PMID: 10592954
-
Adverse events related to medications identified by a Canadian poison centre.J Popul Ther Clin Pharmacol. 2011;18(2):e250-6. Epub 2011 May 2. J Popul Ther Clin Pharmacol. 2011. PMID: 21576730
-
The state of dietary supplement adverse event reporting in the United States.Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):962-70. doi: 10.1002/pds.1627. Pharmacoepidemiol Drug Saf. 2008. PMID: 18613260 Review.
-
Drug identification: a survey of poison control centers.J Toxicol Clin Toxicol. 2004;42(4):371-81. doi: 10.1081/clt-120039543. J Toxicol Clin Toxicol. 2004. PMID: 15461245
-
Improving the reporting of adverse drug reactions in the hospital setting.Postgrad Med. 2010 Nov;122(6):154-64. doi: 10.3810/pgm.2010.11.2233. Postgrad Med. 2010. PMID: 21084792 Review.
Cited by
-
Medical Toxicology and COVID-19: Our Role in a Pandemic.J Med Toxicol. 2020 Jul;16(3):245-247. doi: 10.1007/s13181-020-00778-4. Epub 2020 Apr 30. J Med Toxicol. 2020. PMID: 32356251 Free PMC article. No abstract available.
-
Poisons centres and the reporting of adverse drug events: the case for further development.Drug Saf. 2007;30(3):191-4. doi: 10.2165/00002018-200730030-00002. Drug Saf. 2007. PMID: 17343427 No abstract available.
-
Standardized pill imprint codes: a pharma fantasy.J Med Syst. 2004 Feb;28(1):1-7. doi: 10.1023/b:joms.0000021517.51673.f3. J Med Syst. 2004. PMID: 15171065
-
Prevalence and Use of Dietary Supplements Among Pharmacy Students in Saudi Arabia.Risk Manag Healthc Policy. 2020 Sep 11;13:1523-1531. doi: 10.2147/RMHP.S256656. eCollection 2020. Risk Manag Healthc Policy. 2020. PMID: 32982510 Free PMC article.
-
Intelligent Telehealth in Pharmacovigilance: A Future Perspective.Drug Saf. 2022 May;45(5):449-458. doi: 10.1007/s40264-022-01172-5. Epub 2022 May 17. Drug Saf. 2022. PMID: 35579810 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous